Docetaxel and Capecitabine for First Line Treatment of Metastatic Squamous Cell Carcinoma of the Head & Neck
Status:
Terminated
Trial end date:
2007-09-01
Target enrollment:
Participant gender:
Summary
Recent progress in treatment of recurrent/metastatic SCCHN has been made with the
introduction of the taxanes. Docetaxel as a single agent has a response rate of 22-42% and
17% in patients with recurrent disease. Capecitabine is an oral fluoropyrimidine prodrug that
is converted into 5-FU. Previous studies have shown that the capecitabine/docetaxel
combination has a synergistic inhibition of tumor growth, resulting in significantly superior
efficacy in time to disease progression (TTP), overall survival, median survival and
objective tumor response rate compared to docetaxel alone.
This trial will investigate the efficacy the combination of docetaxel and capecitabine in
treating patients with recurrent/metastatic SCCHN.